CTLA4 and cancer: Their ability to reshape the TME, synergize with ICIs (e.g., anti-PD-1 and anti-CTLA-4 therapies), and directly enhance T cell function positions them as powerful tools in the next generation of cancer immunotherapy (40, 128).